Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Follow-Up Questions
IPHYF 주식의 가격 성능은 어떻습니까?
IPHYF의 현재 가격은 $2이며, 전 거래일에 decreased 0% 하였습니다.
Innate Pharma SA의 주요 사업 주제나 업종은 무엇입니까?
Innate Pharma SA은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Innate Pharma SA의 시가총액은 얼마입니까?
Innate Pharma SA의 현재 시가총액은 $184.3M입니다
Innate Pharma SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 9명의 분석가가 Innate Pharma SA에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 5명의 매수, 2명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
